Remacemide hydrochloride (BioDeep_00000693637)
代谢物信息卡片
Remacemide hydrochloride
化学式: C17H21ClN2O (304.1342326)
中文名称: 2-氨基-N-(1-甲基-1,2-二苯乙基)乙酰胺盐酸盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(CC1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)CN.Cl
InChI: 1H
描述信息
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents
D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
C78272 - Agent Affecting Nervous System
D020011 - Protective Agents
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- O Devinsky, B Vazquez, E Faught, I E Leppik, J M Pellock, S Schachter, V Alderfer, T A H Holdich. A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment.
Seizure.
2002 Sep; 11(6):371-6. doi:
10.1053/seiz.2001.0669. [PMID: 12160664] - E J Popke, R Patton, G D Newport, L G Rushing, C M Fogle, R R Allen, E C Pearson, T G Hammond, M G Paule. Assessing the potential toxicity of MK-801 and remacemide: chronic exposure in juvenile rhesus monkeys.
Neurotoxicology and teratology.
2002 Mar; 24(2):193-207. doi:
10.1016/s0892-0362(02)00206-4. [PMID: 11943507] - M W Jones, W T Blume, A Guberman, M A Lee, N Pillay, D F Weaver, F Veloso, T A H Holdich. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen.
Seizure.
2002 Mar; 11(2):104-13. doi:
10.1053/seiz.2002.0589. [PMID: 11945097] - D W Chadwick, T A Betts, H G Boddie, P M Crawford, P Lindstrom, P K Newman, I Soryal, S Wroe, T A H Holdich. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen.
Seizure.
2002 Mar; 11(2):114-23. doi:
10.1053/seiz.2002.0588. [PMID: 11945098] - F M Besag, R E Newton, G E Blakey, A D Dean. Safety, tolerability, and pharmacokinetics of remacemide in children.
Pediatric neurology.
2001 May; 24(5):352-6. doi:
10.1016/s0887-8994(01)00256-9. [PMID: 11516608] - W D Hooper, M J Eadie, G E Blakey, J A Lockton, M Manun'Ebo. Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males.
British journal of clinical pharmacology.
2001 Mar; 51(3):249-55. doi:
10.1046/j.1365-2125.2001.00338.x. [PMID: 11298071] - A Richens, G Mawer, P Crawford, B Harrison. A placebo-controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy.
Seizure.
2000 Dec; 9(8):537-43. doi:
10.1053/seiz.2000.0447. [PMID: 11162750] - D Chadwick, D Smith, P Crawford, B Harrison. Remacemide hydrochloride: a placebo-controlled, one month, double-blind assessment of its safety, tolerability and pharmacokinetics as adjunctive therapy in patients with epilepsy.
Seizure.
2000 Dec; 9(8):544-50. doi:
10.1053/seiz.2000.0448. [PMID: 11162751] - A G Dyker, K R Lees. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke.
Stroke.
1999 Sep; 30(9):1796-801. doi:
10.1161/01.str.30.9.1796. [PMID: 10471426] - NULL. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group.
Clinical neuropharmacology.
1999 Jul; 22(4):220-5. doi:
NULL. [PMID: 10442252] - G E Mawer, V Jamieson, S B Lucas, J M Wild. Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy.
Epilepsia.
1999 Feb; 40(2):190-6. doi:
10.1111/j.1528-1157.1999.tb02074.x. [PMID: 9952266] - J P Leach, J Girvan, V Jamieson, T Jones, A Richens, M J Brodie. Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients.
Seizure.
1997 Jun; 6(3):179-84. doi:
10.1016/s1059-1311(97)80003-9. [PMID: 9203245] - J P Leach, J Girvan, V Jamieson, T Jones, A Richens, M J Brodie. Mutual interaction between remacemide hydrochloride and phenytoin.
Epilepsy research.
1997 Jan; 26(2):381-8. doi:
10.1016/s0920-1211(96)01005-4. [PMID: 9095400] - P N Patsalos, J W Sander. Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Drug safety.
1994 Jul; 11(1):37-67. doi:
10.2165/00002018-199411010-00005. [PMID: 7917080] - M Bialer. Comparative pharmacokinetics of the newer antiepileptic drugs.
Clinical pharmacokinetics.
1993 Jun; 24(6):441-52. doi:
10.2165/00003088-199324060-00002. [PMID: 8513648] - J W Flynn, J E O'Brien. High-performance liquid chromatographic method for the simultaneous measurement of remacemide (a novel anticonvulsant and cerebroprotectant) and an active metabolite in human plasma.
Journal of chromatography.
1992 Nov; 583(1):91-7. doi:
10.1016/0378-4347(92)80348-t. [PMID: 1484096] - T C Wilson, M S Eisman, G E Machulskis. Quantitation of the novel anticonvulsant remacemide in rat and dog plasma and urine: application of the plasma methodology to measure the plasma protein binding of remacemide.
Journal of chromatography.
1992 Nov; 582(1-2):195-202. doi:
10.1016/0378-4347(92)80319-l. [PMID: 1491041] - G C Palmer, R J Murray, T C Wilson, M S Eisman, R K Ray, R C Griffith, J J Napier, M Fedorchuk, M L Stagnitto, G E Garske. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide.
Epilepsy research.
1992 Jun; 12(1):9-20. doi:
10.1016/0920-1211(92)90086-9. [PMID: 1388119]